Redwood AI Corp. (CSE: AIRX) (OTCQB: RDWCF) (Frankfurt: Y0N) (WKN: A422EZ) has been named a co-applicant in a competitive Terry Fox Research Institute grant awarded to advance Onco-Innovations' SynoGraph(TM) oncology platform. The project, titled “Causal AI to Predict First-in-Human Clinical Outcomes from Preclinical and Real-World Clinico-Genomic Data,” will investigate whether causal AI can improve predictions of first-in-human clinical outcomes using preclinical and real-world clinico-genomic data. The collaboration, announced on September 22, positions Redwood AI Corp. alongside Onco-Innovations as lead applicant, the Michael Smith Genome Sciences Centre, and the Centre de recherche du CHU de Québec-Université Laval. This initiative matters because it could accelerate drug development by enhancing the accuracy of preclinical-to-clinical translation, potentially reducing the time and cost of bringing new therapies to patients.
Redwood AI will contribute proprietary data integration and physicochemical modelling methods to expand SynoGraph's predictive capabilities. The grant supports a project with an estimated budget of $3.5 million and reimburses eligible costs up to 25% of that amount. Academic partners will provide clinico-genomic and imaging data for research using federated learning, which is intended to support analysis while protecting data privacy. For investors, this involvement signals Redwood AI's growing role in the healthcare AI sector and validates its technology in a high-stakes research environment. The latest news and updates relating to RDWCF are available in the company's newsroom at https://ibn.fm/RDWCF.
The project's focus on causal AI distinguishes it from traditional correlation-based models. By integrating diverse data sources and employing physicochemical modelling, the team aims to create a more robust framework for predicting how drugs will behave in humans. If successful, this could lead to more efficient clinical trials and higher success rates, ultimately benefiting patients and the broader healthcare system. The involvement of the Terry Fox Research Institute, a renowned Canadian cancer research organization, adds significant credibility to the endeavor. The announcement was disseminated through AINewsWire, a specialized communications platform focused on artificial intelligence advancements, which is part of the Dynamic Brand Portfolio at IBN. IBN provides access to a vast network of wire solutions via InvestorWire to efficiently reach target markets, along with article and editorial syndication to 5,000+ outlets and enhanced press release enhancement to ensure maximum impact. For more details, see the full announcement at Read More>>.
This collaboration underscores the increasing convergence of AI and oncology research. By leveraging federated learning, the project also addresses critical data privacy concerns, allowing institutions to collaborate without sharing sensitive patient data directly. Redwood AI's participation not only elevates its profile but also contributes to the broader adoption of AI in clinical research. As the project progresses, stakeholders will watch closely for outcomes that could reshape how new cancer treatments are developed and tested.
